NA-Selank Amidate is the doubly-modified version of Selank — combining N-terminal acetylation (NA-) and C-terminal amidation (-amidate) modifications that together produce the most pharmacokinetically stable and bioavailable form of the Selank peptide sequence. Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is derived from tuftsin and was developed at the Institute of Molecular Genetics in Moscow as an anxiolytic and nootropic peptide. NA-Selank Amidate extends the biological activity duration and improves CNS delivery of the parent compound through modifications that protect both termini from enzymatic degradation.

N-acetylation at the N-terminal threonine blocks aminopeptidase cleavage (the primary route of N-terminal degradation in plasma and tissue), while C-terminal amidation replaces the free carboxylate group with an amide — protecting against carboxypeptidase degradation and producing a neutral C-terminus that more closely mimics the charge state of many endogenous neuropeptides. Together, these modifications extend the peptide's plasma half-life from minutes (unmodified Selank) to significantly longer durations, increasing the AUC (area under the curve) of active peptide per dose and requiring less frequent re-dosing for sustained effects.

The anxiolytic mechanism of Selank involves GABAergic modulation (increasing the sensitivity of GABA-A receptors and potentiating GABA's inhibitory signaling in the amygdala and limbic system), serotonergic upregulation (increases brain serotonin levels through 5-HTP pathway stimulation), and direct neurotrophin activity (upregulates BDNF expression in hippocampus and cortex). The combination of GABAergic and serotonergic effects produces anxiolysis without the sedation, dependence, or cognitive impairment of benzodiazepines — Selank's anxiolysis is "clean," leaving alertness and cognitive performance intact or enhanced.

Beyond anxiety reduction, NA-Selank Amidate produces cognitive enhancement effects independent of its anxiolytic activity. Improved memory consolidation, enhanced attention and focus, and faster information processing have been reported in both research contexts and among users. The mechanism for cognitive enhancement likely involves the BDNF upregulation (improving hippocampal synaptic plasticity) and the GABAergic balance optimization (reducing the anxiety-related cognitive interference that impairs performance under stress). This dual anxiolytic-nootropic profile makes NA-Selank Amidate one of the most comprehensively useful cognitive peptides — it both calms anxious cognition and actively enhances performance.

The immune regulatory effects of Selank add a third dimension: enkephalin-related peptides and tuftsin derivatives like Selank modulate cytokine production and NK cell activity. Selank has been shown to increase T-lymphocyte activity and normalize the inflammatory cytokine imbalances associated with chronic stress — an immunological benefit that complements its neurological effects in high-stress contexts.

Protocol: 250–500mcg intranasal per dose, 1–2× daily. NA-Selank Amidate is ideal for intranasal delivery due to the stability improvements enabling reliable CNS access.